Nuclear factor-kappaB as a molecular target for migraine therapy

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Nitric oxide (NO), generated by inducible NO synthase (iNOS), plays a role in immune and inflammatory responses.
• Glyceryl trinitrate (GTN), an NO donor, can induce delayed migraine attacks and inflammation in rodent dura mater.
• iNOS and inflammation are recognized as potential therapeutic targets for various conditions.

Purpose of the Study:

• To investigate the transcriptional regulation of iNOS following GTN infusion in the dura mater.
• To evaluate the consequences of inhibiting iNOS and associated inflammatory pathways.
• To explore the potential of targeting NF-kappaB for anti-migraine drug development.

Main Methods:

• Intravenous infusion of GTN in a rodent model.
• Administration of L-N(6)-(1-iminoethyl)lysine, a selective iNOS inhibitor.
• Assessment of nuclear factor kappa B (NF-kappaB) activity via IkappaBalpha degradation.
• Treatment with parthenolide, an NF-kappaB inhibitor and constituent of feverfew.

Main Results:

• GTN infusion increased NO production in macrophages and induced iNOS expression and delayed inflammation in the dura mater.
• iNOS expression was preceded by increased NF-kappaB activity, indicated by IkappaBalpha degradation.
• Parthenolide treatment attenuated IkappaBalpha degradation, NF-kappaB activation, and iNOS expression.

Conclusions:

• GTN promotes NF-kappaB activity and inflammation in the dura mater, mimicking the timing of migraine attacks.
• Blockade of NF-kappaB activity presents a novel transcriptional target for developing anti-migraine therapeutics.
• These findings support the exploration of parthenolide and similar compounds for migraine treatment.